(Total Views: 520)
Posted On: 08/27/2025 11:09:47 AM
Post# of 156696
Bingo!!
While there is no announced formal partnership or ongoing clinical trial between Cytodyn and Merck, Cytodyn's research and press releases indicate they are actively exploring the potential of leronlimab to be used in combination with immune checkpoint inhibitors (ICIs), specifically citing pembrolizumab (Keytruda) as an example.
The scientific hypothesis is that leronlimab's ability to increase PD-L1 expression on tumor cells could make patients who would otherwise be ineligible for or unresponsive to ICIs more responsive to drugs like Keytruda.
While there is no announced formal partnership or ongoing clinical trial between Cytodyn and Merck, Cytodyn's research and press releases indicate they are actively exploring the potential of leronlimab to be used in combination with immune checkpoint inhibitors (ICIs), specifically citing pembrolizumab (Keytruda) as an example.
The scientific hypothesis is that leronlimab's ability to increase PD-L1 expression on tumor cells could make patients who would otherwise be ineligible for or unresponsive to ICIs more responsive to drugs like Keytruda.
(5)
(0)
